{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:26:35Z","timestamp":1791476795312,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T00:00:00Z","timestamp":1681516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40259-023-00591-9","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T10:02:01Z","timestamp":1681552921000},"page":"569-581","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method"],"prefix":"10.1007","volume":"37","author":[{"given":"Hyunsoo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunkyoung","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seokku","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miju","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikwon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taekyung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,15]]},"reference":[{"key":"591_CR1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, Fakhouri F, Roumenina LT, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643\u201357.","journal-title":"Nat Rev Nephrol"},{"key":"591_CR2","unstructured":"US FDA. Scientific considerations in demonstrating biosimilarity to a reference product. https:\/\/www.fda.gov\/media\/82647\/download. Accessed 26 Sep 2022."},{"key":"591_CR3","unstructured":"US FDA. Development of therapeutic protein biosimilars: comparative analytical assessment and other quality-related considerations. https:\/\/www.fda.gov\/media\/159261\/download. Accessed 26 Sep 2022."},{"key":"591_CR4","unstructured":"European Medicines Agency. Soliris. Summary of product characteristics. 2020. europa.eu. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/soliris. Accessed 8 Aug 2022."},{"key":"591_CR5","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products (revision 1). 2014. europa.eu. https:\/\/www.ema.europa.eu\/en\/similar-biological-medicinal-products-scientific-guideline. Accessed 26 Sept 2022."},{"issue":"2","key":"591_CR6","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40123-022-00453-7","volume":"11","author":"E Kim","year":"2022","unstructured":"Kim E, Han J, Chae Y, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB11, as Lucentis\u00ae (Ranibizumab) biosimilar. Ophthalmol Ther. 2022;11(2):639\u201352.","journal-title":"Ophthalmol Ther"},{"issue":"6","key":"591_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.5414\/CP204176","volume":"60","author":"HA Lee","year":"2022","unstructured":"Lee HA, Jang H, Jeong D, et al. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects. Int J Clin Pharmacol Ther. 2022;60(6):269\u201379.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"591_CR8","unstructured":"European Medicines Agency. Guidance for similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues. 2015. europa.eu. https:\/\/www.ema.europa.eu\/en\/similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical-clinical-issues. Accessed 26 Sep 2022."},{"key":"591_CR9","unstructured":"European Medicines Agency. Guidance for similar medicinal products containing biotechnology-derived proteins as active substance: quality issues. 2014. europa.eu. https:\/\/www.ema.europa.eu\/en\/similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active-substance. Accessed 26 Sept 2022."},{"key":"591_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40259-021-00492-9","volume":"35","author":"KM Hutterer","year":"2021","unstructured":"Hutterer KM, Ip A, Kuhns S, et al. Analytical similarity assessment of ABP 959 in comparison with eculizumab reference product. BioDrugs. 2021;35:563\u201377.","journal-title":"BioDrugs"},{"key":"591_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40259-018-0319-9","volume":"32","author":"VG Dhara","year":"2018","unstructured":"Dhara VG, Naik HM, Majewska NI, et al. Recombinant antibody production in CHO and NS0 cells: differences and similarities. BioDrugs. 2018;32:571\u201384.","journal-title":"BioDrugs"},{"key":"591_CR12","unstructured":"Pharmaceutical and Medical Devices Agency (PMDA). Soliris review report. Review Reports: Drugs. www.pmda.go.jp. Accessed 8 Aug 2022"},{"key":"591_CR13","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1002\/jps.24444","volume":"104","author":"L Liu","year":"2015","unstructured":"Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci. 2015;104:1866\u201384.","journal-title":"J Pharm Sci"},{"key":"591_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2022.115004","volume":"220","author":"V Gusarova","year":"2022","unstructured":"Gusarova V, Degterev M, Lyagoskin I, et al. Analytical and functional similarity of biosimilar Elizaria\u00ae with eculizumab reference product. J Pharm Biomed Anal. 2022;220: 115004.","journal-title":"J Pharm Biomed Anal"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00591-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-023-00591-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-023-00591-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T12:40:36Z","timestamp":1687437636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-023-00591-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,15]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1007\/s40259-023-00591-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,15]]},"assertion":[{"value":"27 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Samsung Bioepis Co., Ltd, Incheon, Republic of Korea.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hyunsoo Kim, Eunkyoung Hong, Jungmin Lee, Seokku Hong, Jihye Kim, Miju Cho, Yikwon Kim, and Taekyung Yoo are employees of either Samsung Bioepis Co., Ltd, or an organization contracted by Samsung Bioepis Co., Ltd. For the present study, there are no other relationships or activities that could appear to influence the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies involving human participants or animals. All laboratory health and safety procedures have been complied within the course of conducting this experimental work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The data\u00a0sets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"HK and EH contributed to data collection, analysis, and interpretation, and drafting and revision of the manuscript. JL contributed to data discussion and reviewed the manuscript. SH, JK, and MC contributed to method development and testing. YK and TY contributed to study design and assessment plan, and development and authoring of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}